Aevi Genomic Medicine, Inc.
(NASDAQ : GNMX)

( )
GNMX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.59%154.960.0%$1509.75m
NVAXNovavax, Inc. 2.55%79.1878.2%$568.86m
AMGNAmgen, Inc. -1.11%222.541.4%$546.33m
GILDGilead Sciences, Inc. -2.18%67.341.0%$534.08m
BIIBBiogen, Inc. -1.22%219.601.8%$496.23m
BNTXBioNTech SE 2.69%160.700.0%$493.59m
REGNRegeneron Pharmaceuticals, Inc. 0.34%605.252.7%$434.03m
ILMNIllumina, Inc. -3.77%331.783.3%$370.86m
VRTXVertex Pharmaceuticals, Inc. -0.23%226.581.9%$358.72m
SNSSSunesis Pharmaceuticals, Inc. -4.71%2.630.7%$183.85m
EXASEXACT Sciences Corp. -0.42%68.8917.9%$173.71m
INCYIncyte Corp. -0.85%73.522.4%$141.06m
ARNAArena Pharmaceuticals, Inc. -0.29%89.6313.7%$135.69m
BMRNBioMarin Pharmaceutical, Inc. -1.37%83.704.2%$108.53m
CRSPCRISPR Therapeutics AG -1.12%61.840.6%$107.20m

Company Profile

Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.